Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. - Wikidata - thesis-toulmin - TriplyDB

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

http://www.wikidata.org/entity/Q34017373

about

Phosphate and FGF-23 The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis Significant roles of anti-aging protein klotho and fibroblast growth factor23 in cardiovascular disease The role of phosphorus in the development and progression of vascular calcification Pathophysiological roles of FGF signaling in the heart Regulation and function of the FGF23/klotho endocrine pathways Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease Calcium and phosphate impact cardiovascular risk.FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease.Vascular calcification: When should we interfere in chronic kidney disease patients and how?Fibroblast Growth Factor-23-A Potential Uremic Toxin Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21 Predictive Factors of One-Year Mortality in a Cohort of Patients Undergoing Urgent-Start Hemodialysis Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese The systemic nature of CKD.Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III.Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease Non-Linear Heart Rate Variability Indices in the Frequent Hemodialysis Network Trials of Chronic Hemodialysis Patients.Phosphate and cardiovascular disease Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: a cross-sectional study in the chronic renal insufficiency cohort (CRIC).Higher fibroblast growth factor-23 concentrations associate with left ventricular systolic dysfunction in dialysis patients Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS)FGF23/FGFR4-mediated left ventricular hypertrophy is reversible.Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.The use of fibroblast growth factor 23 testing in patients with kidney disease.Effect of niacin on FGF23 concentration in chronic kidney disease.Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent manner Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS).CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.FGF23 induces left ventricular hypertrophy FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.

P2860

Q24610674-253F06F9-4FF9-4FFB-8176-A5383851FEFB Q24625902-842CE5D8-98EF-4F30-A17E-AA19C0A810FD Q26782946-38CAABBE-C471-4B6F-8443-E05A0C37467A Q26823897-91C9193A-DBF9-417F-83BE-B7AB8BB63011 Q26853186-D551EAC4-4B59-4F84-89DF-E518A795851E Q26860470-981588A7-8656-4CC5-B4C8-0ED1794E030E Q26863412-E6E90119-8055-418B-BD75-F688C76B5C38 Q27024043-055E5B0F-7406-4334-9395-B871BDC0F9F4 Q27687570-5F65AA66-9E0C-40FF-95D0-AF821A630D73 Q27687769-F98196C3-0BB7-4ED2-A785-415A5ED6BCBA Q28071582-E063FF06-411D-420E-81EA-23FF5D63324E Q28075648-434EAF86-E574-4CDD-8C22-31961E74F933 Q28084197-E3F20A30-1068-40F7-8C78-4AF8E881E7D3 Q28468444-521743BA-8F07-42DB-82F1-51BE20AAA95B Q28477784-07490822-C93C-455C-8FDE-97CF74739599 Q30234695-BC8C6D35-75EE-4F71-AAC2-2656D23A72ED Q30316351-998C45CC-C5DC-4735-8A09-7F7F00EBFEE5 Q30427104-88DA07BC-73EE-4A7E-929A-341989A4F307 Q30564821-B9C13E55-6A8C-4D49-B61C-AF883E8BB376 Q30658399-8FF0B250-1320-4FF8-AFC5-D3EE40BD5D00 Q30979522-F99C9FC6-75D3-4BA0-8045-38248F7350E7 Q33566596-D9384C97-B10B-4A6C-9694-066794C472D5 Q33591588-AF07C3D1-5D8E-4C76-A8B2-917ABDC26D13 Q33600110-8AE9C38B-BD97-49B8-A49F-F25B093B201D Q33654616-8708D712-0091-4556-9740-12282F5BBCAB Q33694566-E3030941-DFAD-47F2-9E16-7D064A63D50F Q33736093-6245A820-DFA4-4F63-B987-5942D83A0113 Q33791650-E1D24167-24E1-4952-A65D-018A5C85B755 Q33835743-CD666811-F6DD-4D7E-844A-28104D218E23 Q33914268-381FE5DE-9776-4F0E-A8C2-F08060CCE669 Q33937415-0AC39CCB-68C5-4925-8DF3-540BA78F2C53 Q33939707-FA10266E-2B64-411C-A1B8-E6C23F9054E2 Q33940724-8536A7B4-71C3-4B43-8499-15358811B94D Q33974636-8EA1261C-1814-44BE-AE90-61E2886C6AFB Q33988990-21610E96-0381-440A-BD38-6247E708DB68 Q34022484-1D84FD70-64EA-4D1B-85CB-DD7809029D29 Q34027316-147196F2-D7D6-47C6-8702-F5DF1575B1D4 Q34027561-431D480B-6C20-483A-976B-AE31E4EC2954 Q34028891-CF152F9B-DF01-404F-A711-8BAF5FD5A891 Q34035797-585E4449-C13F-4267-820C-AB9EB0541DCD

P2860

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

http://www.wikidata.org/entity/Q34017373

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

@ast

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

@en

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

@nl

type

label

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

@ast

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

@en

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

@nl

prefLabel

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

@ast

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

@en

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

@nl

P1433

Q34017373-14E8C5A7-EB47-49EB-9E19-D36422505E02

P1476

Q34017373-35B8C078-9908-4765-875F-BC16DDF97BF9

P2093

Q34017373-0CA2251A-478D-4B44-98C1-FB1F3E813AEE

Q34017373-314D5255-9D0C-4201-A633-ABEEE63A0B97

Q34017373-32B5C1C8-2C96-4A9C-A2EB-10DE0BFFFE13

Q34017373-5DD25B05-E6A6-4CBF-A97D-6B44036530DF

Q34017373-5E168F6E-3308-4F48-A5B0-96AC4C423106

Q34017373-7674EDE4-24AA-4512-8607-2A3D17F08883

Q34017373-7EA54DB6-48B9-4AE4-9FFB-CD34EFE98A24

Q34017373-82171DEB-CA89-4333-8C35-BBD9B9F4A858

Q34017373-9137DD27-6BB0-4393-AB78-61FD6A5AC9B1

Q34017373-9F4F8F13-D5B5-4107-9C10-864B1813ED9C

P2860

Q34017373-1BDB158C-13D0-472A-8816-FFBA08125672

Q34017373-231F68E9-B44F-4AEF-B125-CD2BD1B8C5A1

Q34017373-27DD934D-96E9-4F36-A6C9-DC080A06D4F6

Q34017373-2B2C6D5A-995A-43AA-95E5-94A6805A046C

Q34017373-2CFFA40F-F82A-45AA-B82F-0702220CA6B4

Q34017373-343B51B4-F93E-400C-9AFB-ECE5AA52BE86

Q34017373-37172503-D2B8-436C-BBA1-C8CE8BB13E53

Q34017373-39C7A9ED-07BA-49AE-AFEA-0060D52DBE78

Q34017373-40B72E97-CC26-4293-81A5-D103A50A3C6A

Q34017373-46FAC3D7-90BC-4CDA-AD5E-9139127A7038

P304

Q34017373-53E76BDD-BA24-4762-AB08-F8E71D23D91B

P31

Q34017373-C54CD7D8-6C80-4E46-9FBC-53D090C1FE00

P356

Q34017373-165A42C1-DEFD-4274-96F2-86163DED56F4

P407

Q34017373-9E0CF2C2-C355-4CD1-B981-4DACCFAA9ED3

P433

Q34017373-D66CBC59-1908-4B76-B5A2-9CA5E9B55914

P478

Q34017373-48B4C351-C979-45AE-BA19-16D5B5992E5E

P50

Q34017373-9C54E6D1-01A1-423D-AE6C-F0CD3C2BF668

Q34017373-A885D074-548A-4C6B-8AE5-657E930E5C8A

Q34017373-B684CAC3-0856-4BDC-B1CC-5E8AEFE99ADD

P577

Q34017373-84A958B1-25EA-452D-AFE0-57FD0A6D0C4B

P5875

Q34017373-62E3FD02-E72B-46A0-A606-2E0EA5F757A0

P698

Q34017373-08B8E95C-BB79-4EFF-8591-6263111E9633

P932

Q34017373-824D8113-0874-45C0-819D-581634108376

P356

CIRCULATIONAHA.108.844506

P1433

P1476

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

@en

P2093

Ammar Sarwar

http://www.w3.org/2001/XMLSchema#string

Christopher deFilippi

http://www.w3.org/2001/XMLSchema#string

Erin Coglianese

http://www.w3.org/2001/XMLSchema#string

Gina Collerone

http://www.w3.org/2001/XMLSchema#string

Karen Laliberte

http://www.w3.org/2001/XMLSchema#string

Kelsey Smith

http://www.w3.org/2001/XMLSchema#string

Myles Wolf

http://www.w3.org/2001/XMLSchema#string

Orlando M Gutiérrez

http://www.w3.org/2001/XMLSchema#string

Robert Christenson

http://www.w3.org/2001/XMLSchema#string

Tamara Isakova

http://www.w3.org/2001/XMLSchema#string

P2860

Coronary Artery Calcium Score Combined With Framingham Score for Risk Prediction in Asymptomatic Individuals

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

How fibroblast growth factor 23 works

Fibroblast growth factor-2 mediates pressure-induced hypertrophic response

Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro

Prevalence of chronic kidney disease in the United States

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23

Left ventricular hypertrophy in the renal patient.

P304

2545-2552

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.108.844506

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Christopher deFilippi

James L Januzzi

P577

2009-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24400964

http://www.w3.org/2001/XMLSchema#string

P698

19414634

http://www.w3.org/2001/XMLSchema#string

P932

2740903

http://www.w3.org/2001/XMLSchema#string